Serum levels of IL-6, IL-8 and CRP as prognostic factors in epithelial ovarian cancer

European Cytokine Network

Volumn 24, Issue 3, 2013, Pages 106-113

  Dobrzycka, Bozena ^a   Mackowiak Matejczyk, Beata ^b   Terlikowska, Katarzyna Maria ^a   Kulesza Bronczyk, Bozena ^a   Kinalski, Maciej ^c   Terlikowski, Slawomir Jerzy ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^b Department of Gynecologic Oncology   (Poland)

^c Department of Gynecology and Obstetrics   (Poland)

Author keywords

C reactive protein (CRP); Epithelial ovarian cancer (EOC); Interleukin 6 (IL 6); Interleukin 8 (IL 8); Prognostic factors

Indexed keywords

C REACTIVE PROTEIN; INTERLEUKIN 6; INTERLEUKIN 8;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CONTROLLED STUDY; DISEASE FREE SURVIVAL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HISTOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MICROPLATE READER; OVARY CARCINOMA; PREOPERATIVE EVALUATION; SURVIVAL RATE; TREATMENT OUTCOME;

C-REACTIVE PROTEIN (CRP); EPITHELIAL OVARIAN CANCER (EOC); INTERLEUKIN-6 (IL-6); INTERLEUKIN-8 (IL-8); PROGNOSTIC FACTORS;

ADULT; AGED; C-REACTIVE PROTEIN; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INTERLEUKIN-6; INTERLEUKIN-8; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PROGNOSIS;

EID: 84888369993     PISSN: 11485493     EISSN: None     Source Type: Journal    
DOI: 10.1684/ecn.2013.0340     Document Type: Article

References (48)

1. Horner MJ, Ries LAG, Krapcho M, et al. (Eds), SEER Cancer Statistics Review, 1975-2006, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2006/, based on November 2008 SEER data submission, posted to the SEER web site, 2009.
2. Stewart BW, Kleihues P. World cancer report. Lyon: IARC Press, 2003.
3. Reports based on data of National Cancer Registry. The Maria Sklodowska-Curie memorial Cancer Center. Department of Epidemiology and Cancer Prevetion, National Cancer Registry 2010, http://epid.coi.waw.pl/krn.
4. Ng JS, Low JJ, Ilancheran A. Epithelial ovarian cancer. Best Pract Res Clin Obstet Gynaecol 2012; 26: 337-45.
5. Macciò A, Madeddu C. Inflammation and ovarian cancer. Cytokine 2012; 58: 133-47.
6. Hunn J, Rodriguez GC. Ovarian cancer: etiology, risk factors, and epidemiology. Clin Obstet Gynecol 2012; 55: 3-23.
7. Clendenen TV, Lundin E, Zeleniuch-Jacquotte A, et al. Circulating inflammation markers and risk of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev 2011; 20: 799-810.
8. Wang Y, Li L, Guo X, et al. Interleukin-6 signaling regulates anchorage-independent growth, proliferation, adhesion and invasion in human ovarian cancer cells. Cytokine 2012; 59: 228-36.
9. Wang Y, Xu RC, Zhang XL, et al. Interleukin-8 secretion by ovarian cancer cells increases anchorage-independent growth, proliferation, angiogenic potential, adhesion and invasion. Cytokine 2012; 59: 145-55.
10. Castell JV, Gomez-Lechon MJ, David M, et al. Recombinant human interleukin-6 (IL-6/BSF-2/HSF) regulates the synthesis of acute phase proteins in human hepatocytes. FEBS Lett 1988; 232: 347-50.
11. Gastl G, Plante M. Bioactive interleukin-6 levels in serum and ascites as a prognostic factor in patients with epithelial ovarian cancer. Methods Mol Med 2001; 39: 121-3.
12. Scambia G, Testa U, Benedetti Panici P, et al. Prognostic significance of interleukin 6 serum levels in patients with ovarian cancer. Br J Cancer 1995; 71: 354-6.
13. Plante M, Rubin SC, Wong GY, et al. Interleukin-6 level in serum and ascites as a prognostic factor in patients with epithelial ovarian cancer. Cancer 1994; 73: 1882-8.
14. Yigit R, Massuger LF, Zusterzeel PL, et al. Cytokine profiles in cyst fluids from ovarian tumors reflect immunosuppressive state of the tumor. Int J Gynecol Cancer 2011; 21: 1241-7.
15. Dijkgraaf EM, Welters MJ, Nortier JW, et al. Interleukin- 6/interleukin-6 receptor pathway as a new therapy target in epithelial ovarian cancer. Curr Pharm Des 2012; 18: 3816-27.
16. Toutirais O, Chartier P, Dubois D, et al. Constitutive expression of TGF-beta1, interleukin-6 and interleukin-8 by tumor cells as a major component of immune escape in human ovarian carcinoma. Eur Cytokine Netw 2003; 14: 246-55.
17. Lin WW, Karin M. A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest 2007; 117: 1175-83.
18. Vendramini-Costa DB, Carvalho JE. Molecular link mechanisms between inflammation and cancer. Curr Pharm Des 2012; 18: 3831-52.
19. Hefler-Frischmuth K, Hefler LA, Heinze G, et al. Serum C-reactive protein in the differential diagnosis of ovarian masses. Eur J Obstet Gynecol Reprod Biol 2009; 147: 65-8.
20. Allin KH, Nordestgaard BG. Elevated C-reactive protein in the diagnosis, prognosis, and cause of cancer. Crit Rev Clin Lab Sci 2011; 48: 155-70.
21. Macciò A, Lai P, Santona MC, et al. High serum levels of soluble IL-2 receptor, cytokines, andCreactive protein correlate with impairment of T cell response in patients with advanced epithelial ovarian cancer. Gynecol Oncol 1998; 69: 248-52.
22. Macciò A, Madeddu C, Massa D, et al. Interleukin-6 and leptin as markers of energy metabolic changes in advanced ovarian cancer patients. J Cell Mol Med 2009; 13: 3951-9.
23. Lane D, Matte I, Rancourt C, et al. Prognostic significance of IL-6 and IL-8 ascites levels in ovarian cancer patients. BMC Cancer 2011 May 30; 11: 210. doi: 10.1186/1471-2407-11-210.
24. Jemal A, Siegel R, Xu J, et al. Cancer statistics. CA Cancer J Clin 2010; 60: 270-300.
25. Edgell T, Martin-Roussety G, Barker G, et al. Phase II biomarker trial of a multimarker diagnostic for ovarian cancer. J Cancer Res Clin Oncol 2010; 136: 1079-88.
26. Gadducci A, Cosio S, Tana R, et al. Serum and tissue biomarkers as predictive and prognostic variables in epithelial ovarian cancer. Crit Rev Oncol Hematol 2009; 69: 12-27.
27. Dobrzycka B, Terlikowski SJ, Kowalczuk O, et al. Circulating levels of TNF-alpha and its soluble receptors in the plasma of patients with epithelial ovarian cancer. Eur Cytokine Netw 2009; 20: 131-4.
28. Kodama J, Miyagi Y, Seki N, et al. (1999) Serum C-reactive protein as a prognostic factor in patients with epithelial ovarian cancer. Eur J Obstet Gynecol Reprod Biol 1999; 82: 107-10.
29. Lambeck AJ, Crijns AP, Leffers N, et al. Serum cytokine profiling as a diagnostic and prognostic tool in ovarian cancer: a potential role for interleukin 7. Clin Cancer Res 2007; 13: 2385-91.
30. Kemik O, Sumer A, Kemik AS, et al. The relationship among acute-phase response proteins, cytokines and hormones in cachectic patients with colon cancer. World J Surg Oncol 2010 Sep 28; 8: 85. doi: 10.1186/1477-7819-8-85.
31. Zingg U, Forberger J, Frey DM, et al. Inflammatory response in ventilated left and collapsed right lungs, serum and pleural fluid, in transthoracic esophagectomy for cancer. Eur Cytokine Netw 2010; 21: 50-7.
32. Snoussi K, Strosberg AD, Bouaouina N, et al. Genetic variation in pro-inflammatory cytokines (interleukin-1beta, interleukin-1alpha and interleukin-6) associated with the aggressive forms, survival, and relapse prediction of breast carcinoma. Eur Cytokine Netw 2005; 16: 253-60.
33. Capone F, Costantini S, Guerriero E, et al. Serum cytokine levels in patients with hepatocellular carcinoma. Eur Cytokine Netw 2010; 21: 99-104.
34. Jee SH, Chu CY, Chiu HC, et al. Interleukin-6 induced basic fibroblast growth factor-dependent angiogenesis in basal cell carcinoma cell line via JAK/STAT3 and PI3-kinase/Akt pathways. J Investig Dermatol 2004; 123: 1169-75.
35. Yang J, Wang Y, Gao Y, et al. Reciprocal regulation of 17betaestradiol, interleukin-6 and interleukin-8 during growth and progression of epithelial ovarian cancer. Cytokine 2009; 46: 382-91.
36. Xu L, Fidler IJ. Interleukin 8: an autocrine growth factor for human ovarian cancer. Oncol Res 2000; 12: 97-106.
37. Wang Y, Yang J, Gao Y, et al. Regulatory effect of e2, IL-6 and IL-8 on the growth of epithelial ovarian cancer cells. Cell Mol Immunol 2005; 2: 365-72.
38. Kassim SK, El-Salahy EM, Fayed ST, et al. Vascular endothelial growth factor and interleukin-8 are associated with poor prognosis in epithelial ovarian cancer patients. Clin Biochem 2004; 37: 363-9.
39. Mahmoud FA, Rivera NI. The role of C-reactive protein as a prognostic indicator in advanced cancer. Curr Oncol Rep 2002; 4(3): 250-5.
40. Toriola AT, Grankvist K, Agborsangaya CB, et al. Changes in pre-diagnostic serum C-reactive protein concentrations and ovarian cancer risk: a longitudinal study. Ann Oncol 2011; 22: 1916-21.
41. Lundin E, Dossus L, Clendenen T, et al. C-reactive protein and ovarian cancer: a prospective study nested in three cohorts (Sweden, USA, Italy). Cancer Causes Control 2009; 20: 1151-9.
42. McSorley MA, Alberg AJ, Allen DS, et al. C-reactive protein concentrations and subsequent ovarian cancer risk. Obstet Gynecol 2007; 109: 933-41.
43. Bertenshaw GP, Yip P, Seshaiah P, et al. Multianalyte profiling of serum antigens and autoimmune and infectious disease molecules to identify biomarkers dysregulated in epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev 2008; 17: 2872-81.
44. Darai E, Detchev R, Hugol D, et al. Serum and cyst fluid levels of interleukin (IL)-6, IL-8 and tumour necrosis factor-alpha in women with endometriomas and benign and malignant cystic ovarian tumours. Hum Reprod 2003; 18: 1681-5.
45. Lokshin AE, Winans M, Landsittel D, et al. Circulating IL-8 and anti- IL-8 autoantibody in patients with ovarian cancer. Gynecol Oncol 2006; 102: 244-51.
46. Gorelik E, Landsittel DP, Marrangoni AM, et al. Multiplexed immunobead-based cytokine profiling for early detection of ovarian cancer. Cancer Epidemiol Biomarkers Prev 2005; 14: 981-7.
47. Avall Lundqvist E, Nordstrom L, Sjovall K, et al. Evaluation of seven different tumour markers for the establishment of tumour marker panels in gynecologic malignancies. Eur J Gynaecol Oncol 1989; 10: 395-405.
48. Hefler LA, Concin N, Hofstetter G, et al. Serum C-reactive protein as independent prognostic variable in patients with ovarian cancer. Clin Cancer Res 2008; 14: 710-4.